Outsmarting cancer: The power of hybrid genomic/proteomic biomarkers to predict drug response

Brent N. Rexer, Carlos L. Arteaga

Research output: Contribution to journalArticle

Abstract

A recent study by Niepel and colleagues describes a novel approach to predicting response to targeted anti-cancer therapies. The authors used biochemical profiling of signaling activity in basal and ligand-stimulated states for a panel of receptor and intracellular kinases to develop predictive models of drug sensitivity. In some cases, the response to ligand stimulation predicted drug response better than did target abundance or genomic alterations in the targeted pathway. Furthermore, combining biochemical profiles with genomic information was better at predicting drug response. This work suggests that incorporating biochemical signaling profiles with genomic alterations should provide powerful predictors of response to molecularly targeted therapies.

Original languageEnglish (US)
Article number303
JournalBreast Cancer Research
Volume16
Issue number2
DOIs
StatePublished - Mar 31 2014

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Outsmarting cancer: The power of hybrid genomic/proteomic biomarkers to predict drug response'. Together they form a unique fingerprint.

  • Cite this